Compare Amylx Pharmaceuticals Inc (AMLX) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Kinross Gold Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.67 (market cap $2.64B), while Kinross Gold Corporation trades at $27.51 (market cap $32.29B). The key difference: Kinross Gold Corporation is far larger — about 12.2× Amylx Pharmaceuticals Inc's market cap, and Kinross Gold Corporation pays a 0.59% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | KGC | |
|---|---|---|
Market Cap | $2.64B | $32.29B |
Sector | Health | Basic Materials |
52-Week High | $24.19 | $38.06 |
52-Week Low | $7.82 | $18.70 |
Enterprise Value | $2.39B | $30.37B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Kinross Gold (KGC) trades at $27.59, up 0.69% with strong fundamental momentum. The company demonstrates robust earnings growth with three consecutive quarterly beats and impressive profitability metrics including 37.52% net margin and 36.95% ROE. Recent S&P upgrade to 'BBB' and positive project developments at Lobo-Marte support the bullish analyst consensus.
Outlook remains positive with 29 analysts showing 58.6% buy ratings and $37.20 consensus target, representing 35% upside. Key risks include gold price volatility and execution challenges at new projects. Strong free cash flow generation and disciplined capital allocation support continued shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
